The effect of HMG-CoA reductase inhibitors on chronic allograft rejection

Emerging Drugs

Volumn 6, Issue 1, 2001, Pages 95-109

  Jones, T ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Acute; Chronic; HMG CoA reductase inhibitors; Hyperlipidaemia; Organ transplantation; Rejection; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; MEVINOLIN; NEFAZODONE; PHENYTOIN; PRAVASTATIN; PROTEINASE INHIBITOR; RIFAMPICIN; SIMVASTATIN; TACROLIMUS;

CANCER RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; IMMUNOSUPPRESSIVE TREATMENT; MYOSITIS; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATION; PRENYLATION; REVIEW;

EID: 0035027051     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.6.1.95     Document Type: Review

References (93)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Statins do more than just lower cholesterol
4. Inhibition of pancreatic adencarcinoma cell growth by lovastatin
5. Statins and the kidney
6. The role of lipid lowering in transplantation
7. Neuroprotective properties of statins in cerebral ischemia and stroke
8. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation
9. Statins for all
10. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolaemia
11. Platelet-dependent thrombin generation in patients with hyperlipidaemia
12. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients
13. The effect of pravastatin on acute rejection after kidney transplantation - A pilot study
14. Effect of pravastatin on outcomes after cardiac transplantation
15. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro
16. Comparison of the effects of simvastatin and pravastatin on acute rejection in renal transplant patients
17. Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats
18. HMG-CoA Reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation
19. Statins and monocytes
20. Inhibition of proinflammatory cytokine production by pravastatin
21. Effects of pravastatin on chronic rejection of rat cardiac allografts
22. Simvastatin decreases accelerated graft vessel disease after heart transplantation in ah animal model
23. Simvastatin reduces graft vessel disease and mortality after heart transplantation
24. Inhibition of monocyte chemotactic protein-1 synthesis by statins
25. Inhibitors of hydroxymethylgutaryl-coenzyme A reductase and risk of fracture among older women
26. Oral statins and increased bone-mineral density in post menopausal women
27. Lovastatin inhibits proliferation of rat mesangial cells
28. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
29. Effects of cerivastatin on human arterial smooth muscle proliferation and migration in transfilter cocultures
30. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthetase
31. Mechanisms of chronic rejection
32. Immunologic and nonimmunologic correlates of chronic renal allograft dysfunction
33. Risk factors for chronic rejection in renal allograft recipients
34. Current thinking on chronic renal allograft rejection: Issues, concerns and recommendations from a 1997 roundtable discussion
35. Progression of renal damage in chronic rejection
36. The role of transforming growth factor beta in chronic renal allograft nephropathy
37. Heterogeneity of cardiac allograft vasculopathy: Clinical insights from coronary angiography
38. Effects of lovastatin on the immune system
39. Does cholesterol lowering cause cancer?
40. Assessing possible hazards of reducing serum cholesterol
41. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study
42. Reversal of lovastatinmediated inhibition of natural killer cell cytotoxicity by interleukin 2
43. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients
44. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience
45. Hyperlipidaemia in renal transplant recipients: Natural history and response to treatment
46. A crossover comparison of the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidaemic organ transplant recipients
47. Cardiac transplantation
48. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation
49. Prevention of chronic heart allograft rejection
50. Coronary artery disease in cardiac transplant recipients
51. Impact of proximal or midvessel discrete coronary artery stenosis on survival after heart transplantation
52. Sudden cardiac death in cardiac transplant recipients
53. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
54. The oxidation hypothesis of atherosclerosis
55. The effect of HMG Co A reductase inhibitors on chronic allograft rejection
56. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are statins mechanistically similar?
57. Pharmacological effects of HMG Co A reductase inhibitors other than lipoprotein modulation
58. Hyperlipidaemia after liver transplantation: Natural htstory and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor - Pravastatin
59. Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidaemia following lung transplantation
60. Effect of immunosuppressive therapy on graft half-life projections
61. Tacrolimus: An update of its pharmacology and clinical efficacy in the management of organ transplantation
62. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients
63. Dialysis and transplantation in the treatment of renal failure
64. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
65. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation
66. Cyclosporine-ketoconazole interaction. Long term follow up and preliminary results of a randomized trial
67. Diltiazem in renal allograft recipients receiving cyclosporine
68. Survey of cyclosporin-sparing agent use in Australasian transplant centres
69. Modulators of dyslipidaemia
70. Concomitant use of cytochrome P4503A4 inhibitors and simvastatin
71. The use of other drugs to allow a lower dosage of cyclosporin to be used
72. Acute heart transplant rejection due to St John's Wort
73. Interaction between lovastatin and cyclosporine a after heart and kidney transplantation
74. Statins after cardiac transplantation: Which statin, what dose and how low should we go?
75. Rhabdomyolysis and renal injury with Lovastatin use: Report of two cases in cardiac transplant recipients
76. Myolysis anal acute renal failure in a heart transplant recipient receiving lovastatin
77. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
78. Letter to editor
79. Which dosage of simvastatin in renal transplant recipients?
80. Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation
81. A study of treatment compliance following kidney transplantation
82. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
83. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A4 and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
84. Clinical modulation of multidrug resistance in multiple myeloma: Effect of cyclosporine on resistant tumour cells
85. Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine
86. Increase in cerivastatin exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
87. Targeting the Ras signalling pathway: A rational, mechanism-based treatment for hematoligic malignancies
88. Inhibition of farnesyltransferase with A-176120, a novel anal potent farnesyl pyrophosphate analogue
89. Novel limonene phosphonate and farnesyl dtphosphate analogues: Design, synthesis and evaluation as potential proteinfarnesyl transferase inhibitors
90. Perrilyl alcohol inhibits TCR-mediated [Ca++] signalling, alters cell shape and motility and induces apoptosis in T lymphocytes
91. Periilyl alcohol, an inhibitor of geranylgeranyl transferase, induces apoptosis of immortalised human vascular smooth muscle cells in vitro
92. Mechanism of perillyl alcohol induced immunosuppression as a new class of immunosuppressive agents